Low-Intensity DOACs in VTE: Sapienza University Reports Long-Term Outcomes
Friends of Mediterranean Journal of Hematology and Infectious Diseases Group shared a post by on LinkedIn:
“Direct oral anticoagulants (DOACs) are widely used for the treatment and secondary prophylaxis of venous thromboembolism (VTE).
Nowadays, DOACs represent the gold standard for long-term anticoagulation, with low-intensity DOAC administration becoming increasingly used worldwide in such scenarios.
Although low-intensity apixaban and rivaroxaban are approved for clinical usage as secondary VTE prophylaxis, there is limited literature regarding their efficacy and safety with a long follow-up.
Here we report the long experience of Sapienza University in Rome.”
Read the full article here.
Article: Secondary Prophylaxis of Venous Thromboembolism (VTE) with low dose Apixaban or Rivaroxaban: Results from a patient population with more than 2 years of median follow-up
Authors: Alessandro Laganà, Giovanni Manfredi Assanto, Chiara Masucci, Mauro Passucci, Livia Donzelli, Alessandra Serrao, Erminia Baldacci, Cristina Santoro, Antonio Chistolini
Stay updated on the latest scientific advances in the field of thrombosis with Hemostasis Today.
-
Aug 12, 2025, 06:39Join an NHLBI Clinical Trial on Blood Clots, Inflammation, and Vascular Disease
-
Aug 11, 2025, 13:40Maxime Dely on Why Ethical Blood Donation Matters
-
Aug 11, 2025, 13:20WFH Humanitarian Aid Program Hosts Workshop on Hemophilia Diagnosis and Management in Türkiye
-
Aug 11, 2025, 12:05New Research on CRISPR’s Hidden Risks: Reviewed by Wolfgang Miesbach
-
Aug 11, 2025, 06:47Daratumumab Maintenance and Multiple Myeloma- Blood Journals Portfolio
-
Aug 12, 2025, 11:08A Rare Case of Aortic Thrombosis in a Newborn With CDH
-
Aug 12, 2025, 03:37Low-Intensity DOACs in VTE: Sapienza University Reports Long-Term Outcomes
-
Aug 12, 2025, 02:00Arsene Mekinian։ International Vexas' Announcements Is Finally Published
-
Aug 12, 2025, 01:27Marco Pirisinu: Highlights Potential of PDEVs in Drug Delivery
-
Aug 11, 2025, 13:50Vascular Damage from Pancreatic Juice Leakage
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 11, 2025, 05:16Andreas Calatzis: Any Information on Soviet Thrombelastographs?
-
Aug 9, 2025, 15:36NBCA: Blood Clot Survivor Runs 2025 NYC Marathon with Team Stop the Clot
-
Aug 8, 2025, 18:33Hemophilia Alliance during Tennessee Hemophilia and Bleeding Disorders Foundation Annual Meeting 2025
-
Aug 7, 2025, 14:49JAMA+AI Conversations: David Rhew's Journey from Clinical Practice to Technology Leadership
-
Aug 6, 2025, 16:47My Clot Story: Birth Control and A Life-threatening Pulmonary Embolism